Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 Jan 15;361(Pt 2):231–241. doi: 10.1042/0264-6021:3610231

The fibroblast growth factor receptor, FGFR3, forms gradients of intact and degraded protein across the growth plate of developing bovine ribs.

Sujata G Pandit 1, Prasanthi Govindraj 1, Joachim Sasse 1, Peter J Neame 1, John R Hassell 1
PMCID: PMC1222303  PMID: 11772395

Abstract

Point mutations in the human fibroblast growth factor (FGF) receptor 3 gene (Fgfr3) produce a constitutively active receptor, which disrupts chondrocyte differentiation in the growth plate and results in skeletal dysplasias with severe shortening of the limbs. Alternative splicing of the Fgfr3 transcript gives rise to two isoforms, IIIc and IIIb, which vary in their specificity for FGF ligands. We examined the expression of these FGFR3 isoforms in the bovine fetal rib growth plate to determine whether levels of FGFR3 expression are zone-related. Transcripts for both Fgfr3 isoforms are expressed in rib growth plate, with maximum expression in the hypertrophic region and the least expression in the reserve zone. Fgfr3 IIIc is the predominant isoform in the growth plate. Western-blot analysis revealed the presence of full-length FGFR3 (135 kDa) for both isoforms in the reserve zone, a major 98 kDa fragment in all zones and smaller fragments primarily in the hypertrophic zone. Immunostaining localized FGFR3 to the pericellular region of reserve chondrocytes and to the extracellular matrix in the hypertrophic zone. These results suggest that the transmembrane form of FGFR3 increasingly undergoes proteolytic cleavage towards the hypertrophic zone to produce an extracellular-domain fragment of FGFR3, which is present in large amounts in the matrix of hypertrophic cells. These findings suggest a proteolytic regulatory mechanism for FGFR3, whereby Fgfr3 fragments could control availability of FGF for the intact receptor, and by which proteolysis could inactivate the receptor.

Full Text

The Full Text of this article is available as a PDF (444.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arikawa-Hirasawa E., Watanabe H., Takami H., Hassell J. R., Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet. 1999 Nov;23(3):354–358. doi: 10.1038/15537. [DOI] [PubMed] [Google Scholar]
  2. Avivi A., Yayon A., Givol D. A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett. 1993 Sep 20;330(3):249–252. doi: 10.1016/0014-5793(93)80882-u. [DOI] [PubMed] [Google Scholar]
  3. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–165. doi: 10.1016/s0065-230x(08)60305-x. [DOI] [PubMed] [Google Scholar]
  4. Bellus G. A., McIntosh I., Smith E. A., Aylsworth A. S., Kaitila I., Horton W. A., Greenhaw G. A., Hecht J. T., Francomano C. A. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet. 1995 Jul;10(3):357–359. doi: 10.1038/ng0795-357. [DOI] [PubMed] [Google Scholar]
  5. Buckwalter J. A., Rosenberg L. C., Ungar R. Changes in proteoglycan aggregates during cartilage mineralization. Calcif Tissue Int. 1987 Oct;41(4):228–236. doi: 10.1007/BF02555243. [DOI] [PubMed] [Google Scholar]
  6. Burgess W. H., Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575–606. doi: 10.1146/annurev.bi.58.070189.003043. [DOI] [PubMed] [Google Scholar]
  7. Chellaiah A. T., McEwen D. G., Werner S., Xu J., Ornitz D. M. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem. 1994 Apr 15;269(15):11620–11627. [PubMed] [Google Scholar]
  8. Chellaiah A., Yuan W., Chellaiah M., Ornitz D. M. Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity. J Biol Chem. 1999 Dec 3;274(49):34785–34794. doi: 10.1074/jbc.274.49.34785. [DOI] [PubMed] [Google Scholar]
  9. Cheon H. G., LaRochelle W. J., Bottaro D. P., Burgess W. H., Aaronson S. A. High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):989–993. doi: 10.1073/pnas.91.3.989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coffin J. D., Florkiewicz R. Z., Neumann J., Mort-Hopkins T., Dorn G. W., 2nd, Lightfoot P., German R., Howles P. N., Kier A., O'Toole B. A. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell. 1995 Dec;6(12):1861–1873. doi: 10.1091/mbc.6.12.1861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. D'Angelo M., Billings P. C., Pacifici M., Leboy P. S., Kirsch T. Authentic matrix vesicles contain active metalloproteases (MMP). a role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-beta. J Biol Chem. 2001 Jan 5;276(14):11347–11353. doi: 10.1074/jbc.M009725200. [DOI] [PubMed] [Google Scholar]
  12. Delezoide A. L., Lasselin-Benoist C., Legeai-Mallet L., Brice P., Senée V., Yayon A., Munnich A., Vekemans M., Bonaventure J. Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses. Hum Mol Genet. 1997 Oct;6(11):1899–1906. doi: 10.1093/hmg/6.11.1899. [DOI] [PubMed] [Google Scholar]
  13. Deng C., Wynshaw-Boris A., Zhou F., Kuo A., Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 1996 Mar 22;84(6):911–921. doi: 10.1016/s0092-8674(00)81069-7. [DOI] [PubMed] [Google Scholar]
  14. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  15. Fosang A. J., Neame P. J., Last K., Hardingham T. E., Murphy G., Hamilton J. A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992 Sep 25;267(27):19470–19474. [PubMed] [Google Scholar]
  16. Garofalo S., Kliger-Spatz M., Cooke J. L., Wolstin O., Lunstrum G. P., Moshkovitz S. M., Horton W. A., Yayon A. Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. J Bone Miner Res. 1999 Nov;14(11):1909–1915. doi: 10.1359/jbmr.1999.14.11.1909. [DOI] [PubMed] [Google Scholar]
  17. Hanneken A., Baird A. Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid. Invest Ophthalmol Vis Sci. 1995 May;36(6):1192–1196. [PubMed] [Google Scholar]
  18. Hanneken A., Frautschy S., Galasko D., Baird A. A fibroblast growth factor binding protein in human cerebral spinal fluid. Neuroreport. 1995 Apr 19;6(6):886–888. doi: 10.1097/00001756-199504190-00015. [DOI] [PubMed] [Google Scholar]
  19. Hanneken A., Maher P. A., Baird A. High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells--implications for the modulation of FGF-2. J Cell Biol. 1995 Mar;128(6):1221–1228. doi: 10.1083/jcb.128.6.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hanneken A., Ying W., Ling N., Baird A. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9170–9174. doi: 10.1073/pnas.91.19.9170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hecht D., Zimmerman N., Bedford M., Avivi A., Yayon A. Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4. Growth Factors. 1995;12(3):223–233. doi: 10.3109/08977199509036882. [DOI] [PubMed] [Google Scholar]
  22. Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S. A., Mankani M., Robey P. G., Poole A. R., Pidoux I. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999 Oct 1;99(1):81–92. doi: 10.1016/s0092-8674(00)80064-1. [DOI] [PubMed] [Google Scholar]
  23. Hou J., Kan M., Wang F., Xu J. M., Nakahara M., McBride G., McKeehan K., McKeehan W. L. Substitution of putative half-cystine residues in heparin-binding fibroblast growth factor receptors. Loss of binding activity in both two and three loop isoforms. J Biol Chem. 1992 Sep 5;267(25):17804–17808. [PubMed] [Google Scholar]
  24. Muenke M., Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet. 1995 Aug;11(8):308–313. doi: 10.1016/s0168-9525(00)89088-5. [DOI] [PubMed] [Google Scholar]
  25. Ornitz D. M., Leder P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J Biol Chem. 1992 Aug 15;267(23):16305–16311. [PubMed] [Google Scholar]
  26. Peters K. G., Werner S., Chen G., Williams L. T. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development. 1992 Jan;114(1):233–243. doi: 10.1242/dev.114.1.233. [DOI] [PubMed] [Google Scholar]
  27. Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J. M., Maroteaux P., Le Merrer M., Munnich A. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994 Sep 15;371(6494):252–254. doi: 10.1038/371252a0. [DOI] [PubMed] [Google Scholar]
  28. Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J. M., Maroteaux P., Le Merrer M., Munnich A. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994 Sep 15;371(6494):252–254. doi: 10.1038/371252a0. [DOI] [PubMed] [Google Scholar]
  29. Scotet E., Houssaint E. The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochim Biophys Acta. 1995 Nov 7;1264(2):238–242. doi: 10.1016/0167-4781(95)00156-b. [DOI] [PubMed] [Google Scholar]
  30. Smale G., Sasse J. RNA isolation from cartilage using density gradient centrifugation in cesium trifluoroacetate: an RNA preparation technique effective in the presence of high proteoglycan content. Anal Biochem. 1992 Jun;203(2):352–356. doi: 10.1016/0003-2697(92)90324-z. [DOI] [PubMed] [Google Scholar]
  31. Speir E. H., Sullivan J., Patterson R. E. A new device for the efficient pulverisation and extraction of myocardial biopsies for high energy phosphate analysis. Cardiovasc Res. 1985 Jul;19(7):449–451. doi: 10.1093/cvr/19.7.449. [DOI] [PubMed] [Google Scholar]
  32. Tavormina P. L., Shiang R., Thompson L. M., Zhu Y. Z., Wilkin D. J., Lachman R. S., Wilcox W. R., Rimoin D. L., Cohn D. H., Wasmuth J. J. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet. 1995 Mar;9(3):321–328. doi: 10.1038/ng0395-321. [DOI] [PubMed] [Google Scholar]
  33. Vu T. H., Shipley J. M., Bergers G., Berger J. E., Helms J. A., Hanahan D., Shapiro S. D., Senior R. M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998 May 1;93(3):411–422. doi: 10.1016/s0092-8674(00)81169-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wang Y., Spatz M. K., Kannan K., Hayk H., Avivi A., Gorivodsky M., Pines M., Yayon A., Lonai P., Givol D. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4455–4460. doi: 10.1073/pnas.96.8.4455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Zhou Z., Apte S. S., Soininen R., Cao R., Baaklini G. Y., Rauser R. W., Wang J., Cao Y., Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052–4057. doi: 10.1073/pnas.060037197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Zimmer Y., Givol D., Yayon A. Multiple structural elements determine ligand binding of fibroblast growth factor receptors. Evidence that both Ig domain 2 and 3 define receptor specificity. J Biol Chem. 1993 Apr 15;268(11):7899–7903. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES